Managed Healthcare Executive August 31, 2021
Mobile devices for patients to report symptoms associated with immune checkpoint inhibitors address an unmet need.
Technology-enabled monitoring of patient-reported outcomes can help manage the immune-related toxic effects patients receiving immune checkpoint inhibitors may experience, according to an interim analysis of a study published in JAMA Open Network.
Investigators hypothesized that a patient-reported outcomes system that could be accessed with mobile devices might facilitate prompt communication between patients at risk for immune toxic effects and their healthcare teams.
They conducted an open-label cohort study at the University of Texas MD Anderson Cancer Center in Houston from September 6, 2019, to September 3, 2020. Fifty patients with genitourinary cancers treated with immune checkpoint inhibitors were enrolled. The primary end point was...
Today's Sponsors
Today's Sponsor